癌症是全球主要的死亡原因，由受各种环境因素影响的基因非遗传性和遗传性改变引发。四氢异喹啉 (THIQ)，特别是 1,2,3,4-四氢异喹啉，是各种生物碱中的基本元素，普遍存在于喹啉和吲哚生物碱附近。在这篇综述中，THIQ 衍生物作为抗癌剂的治疗应用从 2016 年到2024年已审查。这些专利是通过对 Espacenet、Google 专利、WIPO 和 Sci Finder 数据库的综合搜索而收集的。这些专利涵盖的治疗领域包括许多癌症靶点。THIQ 类似物在药物化学中发挥着至关重要的作用，其中许多类似物是药理学过程和临床试验中不可或缺的一部分。许多 THIQ 化合物已被合成用于治疗目的，特别是在癌症治疗中。它们在开发抗癌药物方面显示出巨大的前景，对各种癌症靶点表现出强大的亲和力和功效。多靶点配体的创建是基于 THIQ 的抗癌药物发现的一个引人注目的途径。

Cancer is a prominent cause of death globally, triggered by both non-genetic and genetic alterations in genes influenced by various environmental factors. The tetrahydroisoquinoline (THIQ), specifically 1,2,3,4-tetrahydroisoquinoline serves as fundamental element in various alkaloids, prevalent in proximity to quinoline and indole alkaloids.In this review, the therapeutic applications of THIQ derivatives as an anticancer agent from 2016 to 2024 have been examined. The patents were gathered through comprehensive searches of the Espacenet, Google patent, WIPO, and Sci Finder databases. The therapeutic areas encompassed in the patents include numerous targets of cancer.THIQ analogues play a crucial role in medicinal chemistry, with many being integral to pharmacological processes and clinical trials. Numerous THIQ compounds have been synthesized for therapeutic purposes, notably in cancer treatment. They show great promise for developing anticancer drugs, demonstrating strong affinity and efficacy against various cancer targets. The creation of multi-target ligands is a compelling avenue for THIQ-based anticancer drug discovery.